Whether to take tamoxifen or toremifene for breast cancer treatment before menopause needs to be judged according to the specific symptoms of patients, and what is suitable for the condition is good. Tamoxifen is tamoxifen citrate, which is an anti-estrogenic drug that can inhibit the activity of estrogen, thus reducing the risk of cancer metastasis in premenopausal breast cancer patients, and it can also be used for postoperative adjuvant treatment of early breast cancer. Adverse reactions such as hot flashes, vaginal bleeding, gastrointestinal discomfort, and headache may occur after taking it, and when used by premenopausal women, it may lead to menstrual disorders or amenorrhea. Toremifene, or Toremifene Citrate Tablets, is indicated for postmenopausal women with estrogen receptor-positive or unknown metastatic breast cancer, and can also be used to treat endometrial cancer. Some women experience side effects such as facial flushing, excessive sweating, vaginal bleeding, and fatigue, and long-term use is contraindicated in those with endometrial hyperplasia and severe liver failure. There are also studies showing that menopausal symptoms caused by toremifene are more common than tamoxifen, specific premenopausal breast cancer use but which drug is more appropriate, need to be based on the patient’s specific symptoms and test results, diagnosed by a doctor after the use of medication, can not be taken blindly on their own.